Review of NICE Technology Appraisal Guidance Nos 103/ 134/ 146; on the use of etanerceptand efalizumab for the treatment of adults with psoriasis, infliximab for the treatment ofpsoriasis and adalimumab for the treatment of psoriasis  

Proposal to defer the review

As you may be aware the planned date for review of the above guidance was July 2008.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance. Consequently we propose that the decision to review the original guidance be deferred until 2010 when the evidence base will again be assessed to ascertain the need for a review of the guidance. If and when the decision is taken to update the guidance, it is our intention the update will follow the multiple technology appraisal process.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. 

Please note all comments received will be published on the Institute's website when a decision has been taken. 

For a full list of the organisations we have contacted, please see the document below.

15 October 2008

• Provisional matrix of consultees and commentators